2198. Evaluation of Quantitative Varicella-Zoster Virus Antibody Levels as a Predictor of Zoster Reactivation in HIV-infected Persons
Session: Poster Abstract Session: Host-Pathogen Interactions
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • IDSA Poster--29 Oct 16 Pomerantz.pptx.pdf (860.3 kB)
  • Background: 
    Varicella-zoster virus (VZV) reactivation is common in HIV-infected persons. Although qualitative VZV antibody testing can determine past VZV disease or vaccination, it is unknown whether quantitative VZV antibody levels can predict future zoster development. We evaluated longitudinal quantitative VZV antibody levels in US Military HIV Natural History (NHS) participants with and without a diagnosis of zoster.

    Methods: 
    NHS participants with a zoster diagnosis ≥5 years after HIV diagnosis (n=100) were included as cases. Control participants (n=200) who did not develop zoster were matched by age, race, gender, and CD4 count at HIV diagnosis. Two repository plasma specimens were evaluated using a quantitative anti-VZV ELISA assay, including a baseline level ≥3 years before and a second level 30-180 days prior to zoster diagnosis. Specimen time-points for controls were matched to corresponding cases. Differences in quantitative VZV levels over time were analyzed by paired samples t-tests and ANOVA with Repeated Measures controlling for time intervals between specimens.

    Results:
    Participants were predominantly male (94%) in both groups with a median age of 29 [IQR 24-34] years at HIV diagnosis. The median CD4 count at HIV diagnosis was similar for cases and controls (535 [IQR 384-666] vs 523 [IQR 377-690] cells/uL; p=0.940), however cases had a significantly lower CD4 count at VZV diagnosis compared to controls (436 [IQR 277-631] vs 527 [IQR 367-744] cells/uL; p=0.007). Antiretroviral therapy (ART) use at zoster diagnosis was also lower for cases (52.0%) compared to controls (64.5%; p=0.025). Cases had similar mean VZV antibody levels prior to zoster diagnosis compared to controls (2.25 ± 0.85 vs 2.44 ± 0.96 index value/optical density ratio (OD); p=0.151) and there was no difference in the change in VZV antibody levels over time (0.08 ± 0.71 vs 0.01 ± 0.94 index value/OD per year; p=0.276).

    Conclusion:
    Quantitative VZV levels are stable during the first several years of HIV infection and do not appear to predict future development of zoster. Similar to previous reports, we observed that lower CD4 counts and lack of ART use is more common in those who develop zoster and these characteristics may better predict VZV reactivation in HIV-infected individuals.

    Heather Pomerantz, MD1, Xiaohe Xu, Ph.D.2, James White, BS2, T.S. Sunil, PhD, MPH3, Robert Deiss, MD4, Anuradha Ganesan, MD, MPH5, Brian Agan, MD6 and Jason Okulicz, MD7, (1)Infectious Diseases, San Antonio Military Medical Center, Fort Sam Houston, TX, (2)University of Texas San Antonio, Department of Sociology, San Antonio, TX, (3)Institute for Health Disparities Research, University of Texas at San Antonio, San Antonio, TX, (4)Naval Medical Center San Diego, San Diego, CA, (5)Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, (6)Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, (7)San Antonio Military Medical Center, Infectious Disease Service, Fort Sam Houston, TX

    Disclosures:

    H. Pomerantz, None

    X. Xu, None

    J. White, None

    T. S. Sunil, None

    R. Deiss, None

    A. Ganesan, None

    B. Agan, None

    J. Okulicz, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.